"The Bioasis xB3 patented platform provides researchers with a solution to one of medicine’s most stubborn challenges: how to transport medicines across the blood-brain barrier at doses sufficient to have a therapeutic effect."
Werbung
| Strategie | Hebel | |||
| Steigender BioNTech SE ADR-Kurs | 5,09 | 9,96 | 15,68 | |
| Fallender BioNTech SE ADR-Kurs | 4,90 | 9,46 | 14,47 | |
|
Werbung
| Strategie | Hebel | |||
| Steigender BioNTech SE ADR-Kurs | 5,09 | 9,96 | 15,68 | |
| Fallender BioNTech SE ADR-Kurs | 4,90 | 9,46 | 14,47 | |
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| Bioasis Technologies: blood-brain barrier (BBB) | banditolino | 25.04.21 11:41 |